Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06443671
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-05
First Post:
2024-05-30
Brief Title:
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMRMSS Locally Advanced Rectal Cancer
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-06-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-06-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-30
First Submit QC Date:
May 30 2024
Study First Post Date:
2024-06-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-30
Last Update Post Date:
2024-06-05
Last Update Post Date Type:
ACTUAL